Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 4 | 5 | 9 |
| 2008 | 3 | 14 | 17 |
| 2009 | 5 | 3 | 8 |
| 2010 | 8 | 11 | 19 |
| 2011 | 7 | 7 | 14 |
| 2012 | 8 | 7 | 15 |
| 2013 | 10 | 14 | 24 |
| 2014 | 18 | 10 | 28 |
| 2015 | 17 | 6 | 23 |
| 2016 | 20 | 14 | 34 |
| 2017 | 16 | 12 | 28 |
| 2018 | 22 | 6 | 28 |
| 2019 | 12 | 13 | 25 |
| 2020 | 18 | 11 | 29 |
| 2021 | 24 | 13 | 37 |
| 2022 | 2 | 17 | 19 |
| 2023 | 3 | 16 | 19 |
| 2024 | 17 | 6 | 23 |
| 2025 | 16 | 8 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Simultaneous Presentation of Cutaneous Waldenstr?m Macroglobulinemia and Acalabrutinib-Related Toxicity. Am J Dermatopathol. 2025 Oct 01; 47(10):786-789.
-
Src/FN1 pathway activation drives tumor cell cluster formation and metastasis in lung cancer: A promising therapeutic target. Sci Adv. 2025 Jul 11; 11(28):eadv7377.
-
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease. Am J Physiol Heart Circ Physiol. 2025 Aug 01; 329(2):H490-H504.
-
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. Neuro Oncol. 2025 Jun 21; 27(5):1341-1355.
-
Characterizing the metabolites of the tyrosine-kinase inhibitor pexidartinib in mouse feces, urine, plasma, and liver. J Pharm Biomed Anal. 2025 Nov 15; 265:117034.
-
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits. Mol Cancer Ther. 2025 Jun 04; 24(6):859-869.
-
Diagnosis and Management of Waldenstrom's Macroglobulinemia. Hematol Oncol. 2025 Jun; 43 Suppl 2:e70071.
-
Comprehensive evaluation of phosphoproteomic-based kinase activity inference. Nat Commun. 2025 May 22; 16(1):4771.
-
Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Lett. 2025 Aug 10; 625:217814.